GlassScriptPhysician profile
Thomas Francis Lanchoney
NPI 1578666111
$6,817.76
in general payments reported to CMS, 2019-2025
45 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $976 · 2021: $918 · 2022: $845 · 2023: $908 · 2024: $851 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,564 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.58 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,098.79 | 2019-2025 | Xtandi, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $789.35 | 2019-2025 | Provenge |
| Axonics, INC. | $767.43 | 2020-2024 | Axonics, Bulkamid |
| Abbvie INC. | $517.31 | 2021-2025 | |
| Janssen Biotech, INC. | $506.79 | 2019-2024 | Erleada |
| Teleflex LLC | $484.87 | 2020-2025 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $295.61 | 2019-2020 | |
| Allergan, INC. | $259.78 | 2019-2022 | |
| Pfizer INC. | $241.11 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $212.08 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $152.40 | 2024-2025 | Gemtesa, Orgovyx |
| Merck Sharp & Dohme LLC | $116.72 | 2020-2022 | |
| Acerus Pharmaceuticals Corporation | $110.19 | 2020-2021 | |
| Medtronic, INC. | $108.91 | 2023-2025 | Interstim |
| Urogen Pharma, INC. | $101.07 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lanchoney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.